Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer Arielle HeekeMaria Raquel NunesFilipa Lynce Systemic Therapies (M Liu and T Haddad, Section Editors) Open access 25 October 2018 Pages: 241 - 250
Use of Multigene Prognostic Indices to Guide Clinical Decision-Making Regarding Adjuvant Systemic Therapy Karthik V. GiridharMinetta C. Liu Systemic Therapies (M Liu and T Haddad, Section Editors) 19 November 2018 Pages: 251 - 261
Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer Evanthia T. Roussos TorresRoisin M. Connolly Systemic Therapies (M Liu and T Haddad, Section Editors) 06 November 2018 Pages: 262 - 273
Novel Agents for the Management of Endocrine Resistant Breast Cancer Sonya Reid-LawrenceIngrid A. Mayer Systemic Therapies (M Liu and T Haddad, Section Editors) 15 November 2018 Pages: 274 - 281
Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC) Zorawar S. NoorAashini Master Clinical Trials (PF Peddi, Section Editor) 06 October 2018 Pages: 282 - 288
Updates on Molecular Classification of Triple Negative Breast Cancer Nkiruka EzenwajiakuCynthia X. MaFoluso O. Ademuyiwa Clinical Trials (PF Peddi, Section Editor) 24 September 2018 Pages: 289 - 295
Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018 Rashmi K. MurthyMariana Chavez-MacGregorGabriel N. Hortobagyi Clinical Trials (PF Peddi, Section Editor) 27 July 2018 Pages: 296 - 306
Phased Implementation as a Strategy for Stepwise, Sustainable Improvement in Breast Healthcare in Low-Resource Settings Catherine DugganBenjamin O. Anderson Global Breast Cancer (BO Anderson and C Duggan, Section Editors) 20 October 2018 Pages: 307 - 312
Non-hormonal Chemoprevention Naomi HoddeMarie E. Wood Risk and Prevention (ME Wood, Section Editor) 23 October 2018 Pages: 313 - 318